Authors' Reply

Abstract

Get full access to this article

View all access options for this article.

References

Greene

. Fatal infections associated with mifepristone-induced abortion. N Engl J Med 2005;353:2317–8.

Guidance for industry. Adverse reactions section of labeling for human prescription drug and biological products—content and format. Rockville, MD: Food and Drug Administration, Office of Training and Communications, Division of Drug Information, HFD-240 Center for Drug Evaluation and Research. www.fda.gov/cder/guidance/index.htm (accessed 2006 Jan 20).

Jensen

, Astley

, Morgan

, Nichols

. Outcomes of suction curettage and mifepristone abortion in the United States: a prospective comparison study. Contraception 1999;59:153–9.

Shangchun

Medical abortion in China. JAMWA 2000;55(suppl):197–200.

Fergusson

, Horwood

, Ridder

. Abortion in young women and subsequent mental health. Child Psychol Psychiatry 2006;47:16–24.

Deneux-Tharaux

, Berg

, Bouvier-Colle

. Underreporting of pregnancy-related mortality in the United States and Europe. Obstet Gynecol 2005;106:684–92.

Saul

Abortion reporting in the United States: an examination of the federal-state partnership. Farn Plann Perspect 1998;30:244–7.